Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 18;43(3):447–457. doi: 10.1523/JNEUROSCI.1003-22.2022

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 the authors

SfN exclusive license.

PMC Copyright notice

Figure 8. — Dopaminergic medications increase policy complexity and reduce undermatching in Parkinson's patients. A, Matching slope for each group (least-squares estimate ± 95% CI). Young control subjects: 0.424 (0.391–0.458); elderly control subjects: 0.285 (0.250–0.319); patients with Parkinson's disease off dopaminergic medications: 0.215 (0.178–0.252); patients with Parkinson's disease on dopaminergic medications: 0.300 (0.265–0.334). The two Parkinson's disease groups, our groups of interest, are significantly different, since the 95% CI bands do not overlap. B, Change in policy complexity on dopaminergic medication minus off dopaminergic medication for the Parkinson's disease group. Medians are significantly different between groups (Wilcoxon signed-rank test, p < 0.05). C, Change in response times on dopaminergic medication minus off dopaminergic medication for the Parkinson's disease group. Medians are significantly different between groups (Wilcoxon signed-rank test, p < 0.01).